Koios Beverage Corp. (CSE: KBEV; OTC: SNOVF) (the “Company” or “Koios”), is pleased to announce the appointment of CoorsMiller executive Josh Luman to its Advisory Board. The Advisory Board’s purpose is to advise the Company from time to time on issues as requested by the Company, including advising and assisting with business development by and for the Company, and facilitating introductions between the Company and third parties who may be in a position to assist in furthering the goals of the Company.
Luman, the general manager of CoorsMiller affiliate Blue Moon Brewing Company in Denver, Colorado, brings a wealth of experience and knowledge in the beverage industry to Koios. In addition to being an executive with the second-largest brewer in the U.S., Luman co-founded his own brewery, the River Dog Brewing Co. in Ridgeland, South Carolina. He has vast experience building and operating a company, helped by an MBA in marketing.
“We are very excited that Josh has agreed to join our Advisory Board,” said Chris Miller, CEO of the functional beverage company. “He has built his own beverage brand and is an executive at one of the biggest beverage brands in the world. His expertise, wisdom and industry experience are priceless for Koios.
“Josh’s presence on the team not only provides cutting-edge industry knowledge, but his connections in distribution and sales will hopefully open many doors for the Koios brand.”
Added Luman: “The functional beverage market is exploding and I am thrilled to be coming along for that ride,” he said. “This is the go-to drink-of-choice among a new generation of consumers who want low-calorie, nutrient-dense options. Koios’s products are the best on the market and are delicious.”
In connection with Mr. Luman’s appointment, the Company entered into an Advisory Board Agreement dated May 15, 2018, whereby, among other terms, the Company agreed to grant Mr. Luman 50,000 stock options at the exercise price of $0.38 per common share until expiry on May 15, 2021.
Grant of Stock Options
The Company announces that it has granted 50,000 stock options to Mr. Luman for the purchase of up to an aggregate 50,000 common shares of the Company, pursuant to its Stock Option Plan, at a price of $0.38 per common share. Each option granted to Mr. Luman is exercisable until expiry on May 15, 2021. These stock options vest as follows: 12,500 stock options vest on November 15, 2018, 12,500 stock options vest on May 15, 2019, 12,500 stock options vest on November 15, 2019, and 12,500 stock options on May 15, 2020.
About the Company’s Business
The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Together these distributors represent more than 80,000 bricks and mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets. Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.
Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants. Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity. Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.
Koios is one of the only drinks in the world to infuse its products with MCT oil. MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/
On behalf of the Board of Directors of the Company.
KOIOS BEVERAGE CORP.
Chris Miller, CEO and Director
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements with respect to the statement that the Advisory Board member’s expertise will benefit the Company; and the statement with respect to the growth and size of the functional beverage market. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: (i) adverse market conditions; (ii) changes to the growth and size of the functional beverage market; and (iii) consumer acceptance and adoption of functional beverages as compared to other beverages. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s documents filed from time-to-time with the British Columbia Securities Commission on SEDAR at www.sedar.com.
Koios has not conducted any scientific studies on the effects of Koios’ products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’ products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’ products on an individual’s health and wellbeing.
For further information, please contact:
Media and Investor Relations Strategist
For further information: Paula Arab, Media and Investor Relations Strategist, firstname.lastname@example.org, 403-889-9128